INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
2.560
-0.170 (-6.23%)
At close: Aug 1, 2025, 4:00 PM
2.600
+0.040 (1.56%)
After-hours: Aug 1, 2025, 7:48 PM EDT

Company Description

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.

It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer.

It provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs.

It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INmune Bio, Inc.
INmune Bio logo
CountryUnited States
Founded2015
IPO DateFeb 4, 2019
IndustryBiotechnology
SectorHealthcare
Employees22
CEORaymond Tesi

Contact Details

Address:
225 NE Mizner Blvd., Suite 640
Boca Raton, Florida 33432
United States
Phone858 964 3720
Websiteinmunebio.com

Stock Details

Ticker SymbolINMB
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$8.00
CIK Code0001711754
CUSIP Number45782T105
ISIN NumberUS45782T1051
Employer ID47-5205835
SIC Code2836

Key Executives

NamePosition
Dr. Raymond Joseph Tesi M.D.Co-Founder, President, Chief Executive Officer, Chief Medical Officer and Chairman
David J. Moss M.B.A.Chief Financial Officer, Treasurer and Secretary
Dr. Mark William Lowdell Ph.D.Chief Scientific Officer and Chief Manufacturing Officer
Joshua S. Schoonover Esq.General Counsel

Latest SEC Filings

DateTypeTitle
Jul 29, 20258-KCurrent Report
Jul 25, 20258-KCurrent Report
Jul 2, 2025SCHEDULE 13GFiling
Jun 30, 20258-KCurrent Report
Jun 30, 2025424B5Filing
Jun 30, 20258-KCurrent Report
Jun 26, 20258-KCurrent Report
Jun 16, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 16, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 10, 20258-KCurrent Report